OPKO Health, Inc. Announces Hart-Scott-Rodino Filing for Purchase of Shares by Dr. Phillip Frost
MIAMI, Mar 16, 2009 (BUSINESS WIRE) -- OPKO Health, Inc. (NYSE Alternext U.S.:OPK) today announced Phillip Frost, M.D., Chairman and CEO of the Company, has filed a Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR" Act), to allow him to purchase additional shares of OPKO Health's common stock.
Based upon Dr. Frost's recent purchases and possible future purchases, it is expected that his ownership percentage of OPKO will exceed 50% of the Company's outstanding stock. As a result, he is requesting clearance to allow such purchases under the HSR Act and the rules of the Federal Trade Commission relating to the HSR Act.
About OPKO Health, Inc.
Miami-based OPKO is a specialty healthcare company engaged in the development, marketing, and sales of novel agents and both diagnostic and therapeutic devices for the management of ophthalmic diseases. For more information visit the company's website at www.opko.com.
This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation ReformAct of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding future purchase of OPKO stock, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
SOURCE: OPKO Health, Inc.
OPKO Health, Inc.
Steven D. Rubin, 305-575-6015
Copyright Business Wire 2009